RU2180591C2 - Agent for treatment of men with sexual disorders - Google Patents
Agent for treatment of men with sexual disorders Download PDFInfo
- Publication number
- RU2180591C2 RU2180591C2 RU99127647A RU99127647A RU2180591C2 RU 2180591 C2 RU2180591 C2 RU 2180591C2 RU 99127647 A RU99127647 A RU 99127647A RU 99127647 A RU99127647 A RU 99127647A RU 2180591 C2 RU2180591 C2 RU 2180591C2
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- men
- sexual
- phe
- leu
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Изобретение относится к медицине, а именно к сексопатологии. The invention relates to medicine, namely to sexopathology.
Известны лекарственные средства для лечения сексуальных дисфункций у мужчин: гормональные, сосудистые, психотропные, общебиологические, назначаемые, как правило, комплексно (в справочнике "Сексопатология" под ред. проф. Г.С.Васильченко, М., 1990, 574 с.). Known medicines for the treatment of sexual dysfunctions in men: hormonal, vascular, psychotropic, general biological, are prescribed, as a rule, in a complex manner (in the Handbook "Sexopathology", edited by prof. G.S. Vasilchenko, M., 1990, 574 p.) .
Недостатками применения этих лекарственных средств является невысокая эффективность (до 50%), длительность лечения (от 1 месяца до 10 лет), наличие побочных эффектов и осложнений (10-20%). The disadvantages of using these drugs are low efficiency (up to 50%), duration of treatment (from 1 month to 10 years), the presence of side effects and complications (10-20%).
Известно применение гексапептида: Tyr-D-Ala-Gly-Phe-Leu-Arg (даларгина) для лечения язвенной болезни, инфаркта миокарда, гипертонической болезни, купирования обстинентного синдрома при токсикомании (В пособии для врачей "Лекарственные средства", М.Д.Машковский, М., ч.II, с. 171). The use of a hexapeptide is known: Tyr-D-Ala-Gly-Phe-Leu-Arg (dalargin) for the treatment of peptic ulcer, myocardial infarction, hypertension, relief of the underlying syndrome with substance abuse (In the manual for doctors "Medicines", M.D. Mashkovsky, M., part II, p. 171).
В сексологической практике данный гепсапептид ранее не применялся. In sexological practice, this hepsapeptide has not been previously used.
Техническим результатом предлагаемого решения является повышение эффективности лечения (до 70%), сокращение сроков лечения (до 3-4 недель), отсутствие побочных эффектов и осложнений, экономия лекарственных средств (монотерапия). The technical result of the proposed solution is to increase the effectiveness of treatment (up to 70%), reduce the duration of treatment (up to 3-4 weeks), the absence of side effects and complications, save medicines (monotherapy).
Этот результат достигается тем что назначают Tyr-D-Ala-Gly-Phe-Leu-Arg (даларгин) в общепринятой дозе: 2 мг в сутки внутримышечно, ежедневно в течение 3-4 недель. Противопоказаний к назначению препарата нет. This result is achieved by the fact that Tyr-D-Ala-Gly-Phe-Leu-Arg (dalargin) is prescribed in a generally accepted dose: 2 mg per day intramuscularly, daily for 3-4 weeks. There are no contraindications to the purpose of the drug.
Не вытекает из известного уровня техники тот факт, что применение Tyr-D-Ala-Gly-Phe-Leu-Arg (деларгина) в общепринятой дозе будет способствовать повышению терапевтического эффекта, сокращению сроков лечения при отсутствии побочных действий и осложнений при лечении сексуальных дисфункций у мужчин. It does not follow from the prior art that the use of Tyr-D-Ala-Gly-Phe-Leu-Arg (delargin) in a generally accepted dose will increase the therapeutic effect, shorten the treatment time in the absence of side effects and complications in the treatment of sexual dysfunctions men.
Способ осуществляют следующим образом. The method is as follows.
Пациенту с сексуальными дисфункциями в виде расстройств эрекции, эякуляции, снижения либидо и оргастических ощущений назначают Tyr-D-Ala-Gly-Phe-Leu-Arg (даларгин) в общепринятой дозе: 2 мг в сутки внутримышечно ежедневно в течение 3-4 недель. A patient with sexual dysfunctions in the form of erectile dysfunction, ejaculation, decreased libido and orgasmic sensations is prescribed Tyr-D-Ala-Gly-Phe-Leu-Arg (dalargin) in a generally accepted dose: 2 mg per day intramuscularly daily for 3-4 weeks.
Пример 1. Больной К., 1962 г.р., история болезни 25/99 поступил в отдел сексопатологии Московского НИИ психиатрии МЗ РФ с жалобами на сексуальные расстройства в течение 3-х последних лет: снижение либидо, расстройство адекватной эрекции, преждевременное семяизвержение, снижение оргастических ощущений, уменьшение частоты половых актов до 2-3 раз в год. Расстройства появились после перенесенной 3 года назад пневмонии. Example 1. Patient K., born in 1962, medical history 25/99 was admitted to the department of sexopathology at the Moscow Research Institute of Psychiatry of the Ministry of Health of the Russian Federation with complaints of sexual dysfunction over the past 3 years: decreased libido, upset erection, premature ejaculation, a decrease in orgasmic sensations, a decrease in the frequency of sexual intercourse up to 2-3 times a year. Disorders appeared after pneumonia suffered 3 years ago.
При объективном обследовании сомато-неврологической патологии не выявлено. An objective examination of somato-neurological pathology was not detected.
Общий суммарный показатель по вопроснику СФМ (сексуальная формула мужская) -10,5. The total score for the SPS questionnaire (male sexual formula) is -10.5.
Пациенту назначен Tyr-D-Ala-Gly-Phe-Leu-Arg (даларгин) в дозе 2 мг в сутки, внутримышечно, ежедневно в течение 4-х недель. The patient was prescribed Tyr-D-Ala-Gly-Phe-Leu-Arg (dalargin) at a dose of 2 mg per day, intramuscularly, daily for 4 weeks.
Уже через неделю отмечалось повышение либидо с появлением спонтанных эрекций утром и ночью. К концу второй недели пациент стал предпринимать попытки к осуществлению полового акта. При этом адекватная эрекция была недостаточной: введение полового члена удалось с трудом и семяизвержение произошло через 20 с. К концу третьей недели пациент отмечал явное усиление адекватной эрекции, в результате которой ему удалось совершить один удачный половой акт. На четвертой неделе было совершено два половых акта с продолжительностью около трех минут, сопровождающихся яркими оргастическими ощущениями. Побочных эффектов не было. A week later, an increase in libido was noted with the appearance of spontaneous erections in the morning and at night. Towards the end of the second week, the patient began to attempt sexual intercourse. Moreover, an adequate erection was insufficient: the introduction of the penis was difficult and ejaculation occurred after 20 seconds. By the end of the third week, the patient noted a clear increase in an adequate erection, as a result of which he was able to complete one successful sexual intercourse. In the fourth week, two sexual acts were performed with a duration of about three minutes, accompanied by vivid orgasmic sensations. There were no side effects.
Катамнез 6 месяцев: состояние половой сферы стабильное, количество полноценных половых актов 4-5 раз в месяц. Follow-up 6 months: the condition of the genital area is stable, the number of full sexual intercourse is 4-5 times a month.
Таким образом, назначение Tyr-D-Ala-Gly-Phe-Leu-Arg (даларгина) в дозе 2 мг в сутки, внутримышечно, ежедневно в течение 4-х недель пациенту с сексуальными дисфункциями способствовало восстановлению сексуальной активности, при отсутствии побочных явлений и осложенений. Thus, the administration of Tyr-D-Ala-Gly-Phe-Leu-Arg (dalargin) at a dose of 2 mg per day, intramuscularly, daily for 4 weeks, the patient with sexual dysfunctions contributed to the restoration of sexual activity, in the absence of side effects and complications.
Указанным способом проведено лечение 30 мужчин в возрасте от 25 до 42 лет с различными сексуальными дисфункциями. Положительный эффект был отмечен у 21 больного (70%). In this way, 30 men aged 25 to 42 years with various sexual dysfunctions were treated. A positive effect was noted in 21 patients (70%).
Преимуществами предлагаемого средства являются сокращение сроков лечения (до 4-х недель), отсутствие побочных эффектов и осложнений (100%), повышение эффективности лечения (70%), экономия лекарственных средств (монотерапия). The advantages of the proposed tool are the reduction of treatment time (up to 4 weeks), the absence of side effects and complications (100%), increased treatment efficiency (70%), drug savings (monotherapy).
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU99127647A RU2180591C2 (en) | 1999-12-24 | 1999-12-24 | Agent for treatment of men with sexual disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU99127647A RU2180591C2 (en) | 1999-12-24 | 1999-12-24 | Agent for treatment of men with sexual disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU99127647A RU99127647A (en) | 2001-09-20 |
| RU2180591C2 true RU2180591C2 (en) | 2002-03-20 |
Family
ID=20228774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU99127647A RU2180591C2 (en) | 1999-12-24 | 1999-12-24 | Agent for treatment of men with sexual disorders |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2180591C2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008091177A1 (en) | 2007-01-18 | 2008-07-31 | Otkrytoe Aktsionernoe Obschestvo 'otechestvennye Lekarstva' | Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes |
| RU2463054C2 (en) * | 2006-11-03 | 2012-10-10 | Эмоушнл Брэйн Б.В. | Use of testosterone and 5-ht1a agonist for treating sexual dysfunction |
| RU2568844C2 (en) * | 2009-08-26 | 2015-11-20 | Аллерган, Инк. | Methods of treating chronic neurogenic inflammation by modified clostridial toxin |
| US9192669B2 (en) | 2004-05-11 | 2015-11-24 | Eb Ip Lybrido B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| US9333203B2 (en) | 2005-11-11 | 2016-05-10 | Eb Ip Lybrido B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| WO2021211006A1 (en) | 2020-04-13 | 2021-10-21 | Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency | Inhaled hexapeptide for treating interleukin-6 related respiratory diseases |
-
1999
- 1999-12-24 RU RU99127647A patent/RU2180591C2/en active
Non-Patent Citations (1)
| Title |
|---|
| Виноградов В.А. и др. Создание даларгина, история и этапы исследований. Актуальные вопросы гастроэнтерологии. - М.: 1991, с.9-14. Medline: Jackson G.Erectile Dysfunction and cardiovascular disease. Int-J-Clin-Pract, 1999 Jul-Aug. 53(5), 323. * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9192669B2 (en) | 2004-05-11 | 2015-11-24 | Eb Ip Lybrido B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| US10441592B2 (en) | 2004-05-11 | 2019-10-15 | Eb Ip Lybrido B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| US9700566B2 (en) | 2004-05-11 | 2017-07-11 | Eb Ip Lybrido B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| US9737548B2 (en) | 2005-11-11 | 2017-08-22 | Eb Ip Lybrido B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| US9333203B2 (en) | 2005-11-11 | 2016-05-10 | Eb Ip Lybrido B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| US8653051B2 (en) | 2006-11-03 | 2014-02-18 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in combination with a PDE5 inhibitor, in the treatment of sexual dysfunction |
| US8669242B2 (en) | 2006-11-03 | 2014-03-11 | Emotional Brain B.V. | Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction |
| US9211334B2 (en) | 2006-11-03 | 2015-12-15 | Eb Ip Lybridos B.V. | Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction |
| US9597335B2 (en) | 2006-11-03 | 2017-03-21 | Eb Ip Lybridos B.V. | Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction |
| US8648060B2 (en) | 2006-11-03 | 2014-02-11 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in combination with a 5-HT1a agonist, in the treatment of sexual dysfunction |
| US8575139B2 (en) | 2006-11-03 | 2013-11-05 | Emotional Brain B.V. | Use of testosterone and a 5-HT1a agonist in the treatment of sexual dysfunction |
| US10314848B2 (en) | 2006-11-03 | 2019-06-11 | Eb Ip Lybridos B.V. | Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction |
| RU2463054C2 (en) * | 2006-11-03 | 2012-10-10 | Эмоушнл Брэйн Б.В. | Use of testosterone and 5-ht1a agonist for treating sexual dysfunction |
| WO2008091177A1 (en) | 2007-01-18 | 2008-07-31 | Otkrytoe Aktsionernoe Obschestvo 'otechestvennye Lekarstva' | Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes |
| RU2568844C2 (en) * | 2009-08-26 | 2015-11-20 | Аллерган, Инк. | Methods of treating chronic neurogenic inflammation by modified clostridial toxin |
| WO2021211006A1 (en) | 2020-04-13 | 2021-10-21 | Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency | Inhaled hexapeptide for treating interleukin-6 related respiratory diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI280136B (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
| US8389479B2 (en) | Compositions and methods for treatment of multiple sclerosis | |
| AR024074A1 (en) | ABETA FRAGMENT JOINED WITH A BEARING PEPTIDE TO PREVENT OR TREAT DISEASES ASSOCIATED WITH ABETA AMILOID DEPOSITS, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND ITS USE IN THE PREPARATION OF MEDICINES. | |
| US20050245494A1 (en) | Methods to treat one or all of the defined etiologies of female sexual dysfunction | |
| WO2009051628A2 (en) | Transdermal treatment device and method | |
| ES2462553A1 (en) | Composition for improvement of sexual well-being (Machine-translation by Google Translate, not legally binding) | |
| US20120093950A1 (en) | Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occuring age related erectile dysfunction | |
| US6809079B2 (en) | Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide | |
| RU2180591C2 (en) | Agent for treatment of men with sexual disorders | |
| Tegner | Severe skin pain after PUVA treatment | |
| EP0906111B1 (en) | Composition and method for treating herpes simplex | |
| HUE030152T2 (en) | Method for treating disorders of the skin | |
| JPH01261334A (en) | Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof | |
| Goel et al. | Role of L arginine in treatment of osteoporosis | |
| WO2005049053A1 (en) | Composition comprising a magnesium compound and/or a magnesium saltfor improving sexual dysfunction | |
| RU2180223C1 (en) | Agent for treatment of men with erection disorder | |
| Botter | A clinical double-blind comparison of maprotiline and amitriptvline in depression | |
| Shingadiya et al. | Ayurvedic Management of chronic Vitiligo (Shvitra): A case study | |
| US20030118597A1 (en) | Process for production of bee venom as pharmaceutical product which can be used effectively in the treatment of rheumatoid arthritis and viral diseases | |
| RU2161972C2 (en) | Method for applying complex pathogenetic therapy of patients suffering from opisthorchiasis | |
| RU2154490C1 (en) | Method of treatment of men with sexual disorders of diencephalic genesis | |
| RU2192250C2 (en) | Method of treatment of patients with lichen acuminatus | |
| Fazio et al. | Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor | |
| RU2159122C1 (en) | Means and method for improving sperm quality | |
| FR2484257A1 (en) | Poly-vitamin compsns. - for the treatment of all forms of Herpes infection |